{"id":"ser120-1500-ng","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1944647","moleculeType":"Small molecule","molecularWeight":"5872.94"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Without publicly available information on SER120's molecular target or mechanism, the specific biological pathway and therapeutic rationale cannot be determined. The drug designation '1500 ng' likely refers to a dosing or formulation parameter rather than a mechanistic descriptor.","oneSentence":"SER120 is an investigational therapeutic agent in Phase 3 development by Serenity Pharmaceuticals with an undisclosed mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:58.576Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01900704","phase":"PHASE3","title":"Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2013-08","conditions":"Nocturia","enrollment":810},{"nctId":"NCT01357356","phase":"PHASE2, PHASE3","title":"Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia","status":"COMPLETED","sponsor":"Serenity Pharmaceuticals, Inc.","startDate":"2011-05","conditions":"Nocturia","enrollment":750}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SER120 1500 ng","genericName":"SER120 1500 ng","companyName":"Serenity Pharmaceuticals, Inc.","companyId":"serenity-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SER120 is a small molecule being investigated for the treatment of nocturia. It is being studied in a randomized, double-blind, placebo-controlled trial in various doses, including 750 ng/day, 1000 ng/day, and 1500 ng/day.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}